Lifang Pharmaceutical Acquires Ownership of 13 Ophthalmic Solutions for RMB 38 Million

Today, Hefei Lifeon Pharmaceutical Co., Ltd. issued an announcement stating that the company signed the "Agreement on Change of Marketing Authorization Holder" with Anhui Shuangke Pharmaceutical Co., Ltd. on May 10, 2021. Following assessment by Zhongming International Asset Appraisal (Beijing) Co., Ltd. (hereinafter referred to as “Zhongming Appraisal”), Lifeon Pharmaceutical acquired the ownership of drug technologies for 13 eye drop products, including Jinzhen Eye Drops (hereinafter referred to as the “Target Products”), for RMB 38 million, and became the Marketing Authorization Holder for the Target Products.

Basic Information on the Target Product

According to the announcement, the total sales revenue of the target products in 2019 and 2020 was RMB 30.269 million and RMB 17.312 million, respectively.